Artificial Intelligence Identifies Prostate Cancer Patients Who Do Not Need Hormone Therapy
In this article
The era of "de-escalation" (reducing unnecessary treatment) has begun in precision oncology. Artificial intelligence that requires no genetic test and reads only pathology slides says which patient needs hormone therapy with 99% accuracy.
The Clinical Dilemma: Sacrificing Quality of Life While Saving Lives
In the standard treatment of localized prostate cancer, adding Short-Term Hormone Therapy (ADT) to radiotherapy is a frequently used approach. The aim is to starve the cancer by reducing testosterone to zero. But this "better-safe-than-sorry" approach comes at a high cost. Patients struggle for months with:
- Weight gain, insulin resistance, and an increased risk of heart attack.
- Loss of sexual desire and potentially permanent erectile problems.
- Bone loss (osteoporosis) and fracture risk.
- Depression, chronic fatigue, and cognitive slowing.
As physicians, we had long been seeking an answer to the question, "Whom can we safely protect from these adverse effects?" Where the human eye falls short, artificial intelligence has stepped in.
The Solution: "Multimodal Artificial Intelligence" (MMAI) Requiring No Additional Test
The ArteraAI system uses the standard pathology slides already obtained during biopsy. No new tissue sample or genetic tests costing thousands of dollars are needed.
Digital Pathology
Standard pink-purple (H&E)-stained slides are scanned. AI analyzes pixel-level cellular patterns and tissue architecture invisible to the human eye.
Democratic Technology
No tissue wastage, no waiting time. Results reach the physician within 1-2 days. Even a patient in the world's most remote corner can benefit from this advanced technology.
A Historic Turning Point: The 60% Versus 40% Split
In June 2023, NEJM Evidence published results validated using data from the RTOG 9408 study, reshuffling the cards in oncology. AI divided patients into two clear groups:
Group 1: AI Biomarker-Negative (~60% of Patients)
Conclusion: Giving hormone therapy to patients in this group neither prevents metastasis nor prolongs survival. These patients had been enduring the severe adverse effects of treatment for nothing. This group can now safely be spared hormone therapy (de-escalation).
Group 2: AI Biomarker-Positive (~40% of Patients)
Conclusion: For this group, hormone therapy is not an "option" but a "necessity". Adding hormones dramatically reduces the risk of cancer spreading.
The New Era (2024-2025 Updates): Guidelines Have Changed
This achievement did not remain merely an academic publication. Developments over the past 2 years have made ArteraAI part of clinical practice:
- Inclusion in NCCN Guidelines (2024): The world's most respected cancer guideline, NCCN, added this test to its guidelines as the "first and only AI-based predictive test".
- FDA Approval (2025): The FDA granted the system "Breakthrough Device" status.
- The STAMPEDE Study (ASCO 2025): In high-risk patients, it was demonstrated that intensive drugs such as Abiraterone benefit only 25% of patients, while 75% could be spared these toxic drugs.
- Patients with Recurrence (December 2025): A new test answering "Are hormones necessary in salvage treatment?" also became available for patients whose PSA rises after surgery.
The Democratization of Precision Medicine
The era of "standard treatment for everyone" in prostate cancer has ended. ArteraAI is the strongest evidence that AI in oncology can be not merely an "assistant" but a decision-making "actor". Unlike genetic tests, it does not consume tissue, and its cost-effectiveness makes this technology accessible not only to wealthy countries but to the whole world.
Our greatest joy as physicians is to tell a patient, "Your cancer is under control", while also saying, "And don't worry, you do not need hormone therapy; we will protect your heart health and quality of life." This is not science fiction but clinical reality: the age of AI in oncology has officially begun.
Original Sources and Further Reading
- 1. NEJM Evidence (2023): Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer (Spratt DE et al.)
- 2. Urology Times (2024): ArteraAI Prostate Test included in NCCN guidelines
- 3. ASCO JCO (2025): Multimodal AI model to identify benefit from 2nd-generation ARPI in STAMPEDE trial
- 4. Artera Official (Dec 2025): Artera Debuts ArteraAI Prostate Test (Post‑RP)
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.